{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:48Z","timestamp":1792715868806,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108326","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:55:48Z","timestamp":1790366148000},"page":"108326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and associated outcomes in patients with HER2-positive unresectable or metastatic breast cancer: the HER2 REAL Study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-6419","authenticated-orcid":false,"given":"S.C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-667X","authenticated-orcid":false,"given":"C.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-270X","authenticated-orcid":false,"given":"W.-P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Kai Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-6533","authenticated-orcid":false,"given":"S.-A.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2026.108326_bib1","first-page":"355","article-title":"Evolving standards of care and new challenges in the management of HER2-positive breast cancer","volume":"70","author":"Choong","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108326_bib2","first-page":"1045","article-title":"The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies","volume":"10","author":"Kreutzfeldt","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108326_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminoncol.2020.07.008","article-title":"Systemic therapy for metastatic HER2-positive breast cancer","volume":"47","author":"Bredin","year":"2020","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108326_bib4","first-page":"2884","article-title":"De novo metastatic breast cancer: subgroup analysis of molecular subtypes and prognosis","volume":"19","author":"Zhang","year":"2020","journal-title":"Oncol Lett"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108326_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0380","article-title":"Estimated effectiveness of nirsevimab against respiratory syncytial virus","volume":"8","author":"Xu","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108326_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108326_bib7","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108326_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2016.70.2712","article-title":"MARIANNE: impact on current treatment of human epidermal growth factor receptor 2\u2013positive metastatic breast cancer and implications for the future","volume":"35","author":"Jhaveri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108326_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108326_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-025-00753-8","article-title":"HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab","volume":"11","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108326_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108326_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225029","article-title":"A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)","volume":"16","author":"Baek","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"5_Suppl","key":"10.1016\/j.esmoop.2026.108326_bib14","article-title":"Abstract OT3-07-01: real-world data on first-line treatment of HR-positive, HER2-negative, metastatic breast cancer in Brazil (BRAVE Study\/LACOG 0221)","volume":"83","author":"Werutsky","year":"2023","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108326_bib16","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108326_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108326_bib19","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108326_bib20","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108326_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108326_bib22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1186\/s12885-022-10098-1","article-title":"Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes \u2013 an observational cohort study in Sweden","volume":"22","author":"Lindman","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108326_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-016-3705-3","article-title":"Clinical predictors of long-term survival in HER2-positive metastatic breast cancer","volume":"155","author":"Murthy","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108326_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10549-017-4567-z","article-title":"Real-world treatment in patients with HER2+ metastatic breast cancer: treatment decisions in HER2+ mBC","volume":"168","author":"Colomer","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108326_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40487-023-00241-8","article-title":"Real-world treatment patterns and outcomes following first-line pertuzumab and trastuzumab among patients with HER2+ metastatic breast cancer","volume":"11","author":"Mehta","year":"2023","journal-title":"Oncol Ther"},{"key":"10.1016\/j.esmoop.2026.108326_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211059873","article-title":"PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting","volume":"13","author":"Pizzuti","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108326_bib27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s10147-024-02492-5","article-title":"A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice","volume":"29","author":"Varghese","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108326_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-025-07708-4","article-title":"A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable LA\/MBC: final results of the ESTHER study","volume":"212","author":"Ring","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108326_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/fon-2021-0716","article-title":"Real-world treatment of patients with palbociclib for HR+\/HER2-advanced\/metastatic breast cancer: the Europe IRIS Study","volume":"18","author":"Mycock","year":"2022","journal-title":"Fut Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108326_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108326_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108326_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1264861","article-title":"Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer","volume":"13","author":"Kaufman","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108326_bib33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1634\/theoncologist.2012-0414","article-title":"First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER","volume":"18","author":"Tripathy","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108326_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2019.06.014","article-title":"Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study","volume":"118","author":"Le Saux","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108326_bib35","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-18-2366","article-title":"Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERs","volume":"25","author":"Hurvitz","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10371","key":"10.1016\/j.esmoop.2026.108326_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108326_bib37","article-title":"HER2CLIMB-05: phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer","volume":"41","author":"Hamilton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108326_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104417","article-title":"Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: a prognostic analysis based on real-world data comparing Brazil\u2019s public and private healthcare systems","volume":"80","author":"Antonini","year":"2025","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108326_bib39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1634\/theoncologist.2017-0088","article-title":"Disparities of trastuzumab use in resource-limited or resource-abundant regions and its survival benefit on HER2 positive breast cancer: a real-world study from China","volume":"22","author":"Li","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108326_bib40","article-title":"Real-world first-line treatment patterns and outcomes in hormone receptor-positive advanced breast cancer patients: a multicenter, retrospective study in China","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108326_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/jpps.2023.12078","article-title":"Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada","volume":"26","author":"Gambaro","year":"2023","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.esmoop.2026.108326_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2020.10.012","article-title":"Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2\u2013targeted treatments: results from the French personalized reimbursement model database (2011\u20132018)","volume":"141","author":"Cottu","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:41:21Z","timestamp":1792712481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926022684"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108326","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and associated outcomes in patients with HER2-positive unresectable or metastatic breast cancer: the HER2 REAL Study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108326"}}